Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: Chemical structure of ceftazidime.

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques:

Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: MIC 50 , MIC 90 , MIC range, and percent susceptible for ceftazidime–avibactam, ceftazidime, ceftriaxone, and cefepime against Gram-negative aerobic and facultative pathogens 22 , 23 , 25 , 26 , 28 – 30 , 32 – 35

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques:

Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: Activity of ceftazidime–avibactam and comparators against select Gram-negative strict anaerobic bacteria 27 , 32 , 38

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques: Activity Assay, Bacteria

Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: Pharmacokinetic parameters for avibactam administered alone and in combination with ceftazidime

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques:

Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: Phase II clinical trials evaluating ceftazidime in combination with avibactam for Gram-negative bacterial infections

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques: Clinical Proteomics, Infection

Journal: Core Evidence

Article Title: Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections

doi: 10.2147/CE.S40698

Figure Lengend Snippet: Core evidence clinical impact summary

Article Snippet: Assuming a breakpoint of 4 μg/mL (the Clinical and Laboratory Standards Institute [CLSI] Enterobacteriaceae breakpoint for ceftazidime), nearly all isolates of Enterobacteriaceae would be considered susceptible.

Techniques: In Vitro, Activity Assay, Clinical Proteomics